All Biomarkers articles
-
ArticleWhat tissue accumulation can reveal about oligonucleotide safety
Oligonucleotides can remain in tissues long after disappearing from circulation, but does accumulation necessarily indicate toxicity? Dr Tina Rogers examines the evidence needed to interpret preclinical safety findings.
-
NewsYAP/TAZ protein hyperactivity linked to immune evasion via PD-L2 upregulation
Researchers have identified a mechanism by which overactive YAP and TAZ proteins may simultaneously increase cancer cell visibility to the immune system and shield tumours from T-cell attack.
-
ArticleWhy reagent selection belongs inside assay design
High affinity is often a priority when selecting reagents, but does it guarantee better assay performance? Discover why binding kinetics and matrix selectivity matter when developing custom reagents for challenging targets.
-
NewsImmune profiling could help tailor treatment for primary biliary cholangitis
A new review of primary biliary cholangitis reveals how interactions between bile duct epithelial cells and immune populations sustain chronic inflammation, and explores whether mapping individual disease mechanisms could guide more targeted therapies.
-
ArticleEarlier MSA detection could guide alpha-synuclein drug discovery
MSA and Parkinson’s share the same protein pathology, yet MSA progresses far faster. Could earlier detection reveal why and help researchers identify more effective targets for drug discovery?
-
ArticleFinding drug targets through the noise of complex disease
The strongest disease signal may not point to the best drug target. AI could help researchers identify what matters within complex biological networks.
-
NewsExperimental drug reverses paralysis and vision loss in MS mice
A novel inflammasome inhibitor derived from HIV antivirals has reversed established neurological deficits in a preclinical MS model, raising hopes for a restorative approach to a disease where current therapies focus primarily on relapse prevention.
-
ArticleHow protective gene variants are revealing new drug targets
Finding the right drug target remains one of discovery’s biggest challenges. Human genetics is helping researchers strengthen the evidence before committing years of research and investment.
-
ArticleTurning CNS biomarkers into better drug development decisions
Why do promising CNS therapies struggle to translate into patients? Three experts explore how biomarkers can track therapeutic effects, improve patient selection and guide development decisions.
-
WebinarCracking cell dynamics with single-cell proteomics and CRISPR
What can pooled CRISPR screening and protein‑level readouts reveal that transcriptomics alone can’t? Explore how single‑cell genomic perturbations, intracellular protein measurements and surface‑protein profiling expose signalling pathways and clarify antibody specificity.
-
NewsWhole-genome sequencing delivers actionable biomarkers in 73 percent of cancer patients
A large real-world study demonstrates that whole-genome sequencing can identify actionable biomarkers in nearly three-quarters of solid cancer patients.
-
NewsNew malaria mutations linked to resistance against multiple front-line drugs
Whole-genome sequencing of parasites from Ugandan patients has uncovered a cluster of genetic variants linked to reduced susceptibility to multiple front-line malaria treatments, with researchers warning the mutations are spreading rapidly.
-
NewsGLP-1 drug semaglutide extends lifespan and slows ageing in older mice
A new NIH-funded study suggests the GLP-1 receptor agonist semaglutide may slow biological ageing and extend lifespan in older mice, raising the prospect that GLP-1 drugs could one day be developed as broad longevity-enhancing interventions.
-
ArticleWhat makes a human biospecimen fit for purpose in drug discovery
Human biospecimens can bring drug discovery closer to human disease, but their value depends on far more than the sample itself. We explore the factors that determine how much researchers can learn from them.
-
WebinarSpatial proteomics in FFPE tumour tissue: an end-to-end workflow from prostate cancer research
Follow a complete high-plex spatial proteomics workflow on archival FFPE tumour tissue, from marker-panel design to cell phenotyping, with a prostate cancer case study from the University of Surrey.
-
ArticleWhy depression needs a different drug discovery strategy
What if depression is not one disease, but many biologically distinct conditions? A major research programme is investigating what this could mean for biomarkers, drug targets and treatment.
-
NewsNew LOX target discovery could help overcome chemotherapy-resistant breast cancer
A preclinical study has identified lysyl oxidase as an intracellular survival factor in triple-negative breast cancer, with researchers demonstrating that sequentially blocking LOX and a compensatory ferroptosis defence pathway significantly suppresses tumour growth without chemotherapy.
-
WebinarFrom antibody discovery to development: long-read sequencing in practice
As sequencing continues to grow in importance across biotherapeutic discovery and development, where can it make the biggest impact and how can fragmented workflows be overcome?
-
NewsBlood metabolite links ALS progression rate to potential treatment target
A metabolic signal detectable in patient blood has been linked to ALS progression rate and survival, with preclinical data suggesting that boosting levels of the molecule could protect motor neurons and extend survival in disease models.
-
WebinarWhat it really takes to turn cancer discoveries into new therapies
Five leading cancer researchers from across genomics, proteomics, cell biology, chemical biology and gene therapy dig into what’s driving cancer drug discovery forward and what’s still holding progress back.